TOS-358
PI3Kα mutant cancers
Phase 1Active
Key Facts
About Totus Medicines
Totus Medicines is a private, preclinical-to-clinical stage biotech founded in 2019 and headquartered in Cambridge, Massachusetts. The company leverages its proprietary OmniDEL platform—which combines ultra-high-throughput cell-based screening of covalent libraries with AI/ML-powered drug design—to develop oral covalent inhibitors against validated but poorly drugged or previously undruggable targets. Its lead asset, TOS-358, is a covalent PI3Kα inhibitor in Phase 1 trials for oncology, with a discovery program targeting IRF5 in immunology and inflammation. Totus represents a convergence of covalent chemistry, functional genomics, and machine learning aiming to unlock new therapeutic modalities.
View full company profileTherapeutic Areas
Other PI3Kα mutant cancers Drugs
| Drug | Company | Phase |
|---|---|---|
| PI3Kα Program | Cogent Biosciences | Preclinical |